Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-413?

KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.

$1.9 million grant awarded to explore the effect of antifungal drugs in Crohn’s patients

Dr. Iliyan D. Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology, co-director of the Microbiome Core and a

June 15, 2023

TLT Stock analysis and how to profit in the next TLT stock move

August 10, 2023

Opinion | Medicine or Candy? Let’s Reevaluate the Vitamins We Offer to Kids

Meyers is a pediatric pharmacist. They’re hard to miss — the overwhelming number of gummy vitamins available for both adults and children. The past decade

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.